09:54 AM EST, 12/31/2024 (MT Newswires) -- SciSparc ( SPRC ) said Tuesday that the Israeli Medical Cannabis Agency at the Israeli Ministry of Health renewed an approval for the clinical trial of SCI-210 in children with autism spectrum disorder, or ASD.

The 30-day approval is expected to be extended upon final Israeli police approval, expected within the same timeframe, SciSparc ( SPRC ) said.

The SCI-210 clinical trial is a double-blind, randomized, placebo-controlled study at Soroka University Medical Center in Israel, involving 60 children aged 5 to18 with ASD, the pharmaceutical company said.

The 20-week trial will evaluate the efficacy and safety of SCI-210, which is a combination of a proprietary cannabidiol, or CBD, and CannAmide, against standard CBD therapy. The trial will focus on symptom management and therapeutic outcomes, SciSparc ( SPRC ) said, adding that it aims to launch SCI-210 in Israel first, with plans for international expansion pending regulatory approvals.

Price: 0.44, Change: -0.02, Percent Change: -4.98